Tumor initiation and progression are highly intricate biolog-ical processes,and mutation-driven tumorigenesis is a pri-mary underlying cause.Personalized cancer vaccines have been developed to exploit these specific m...Tumor initiation and progression are highly intricate biolog-ical processes,and mutation-driven tumorigenesis is a pri-mary underlying cause.Personalized cancer vaccines have been developed to exploit these specific mutations,particu-larly in the form of tumor neoantigens,to induce immune responses,particularly the activation of CD8+T cells,which can attack malignant cells.Since tumor mutations result in protein sequence alterations distinct from those in normal tissues,therapies that precisely target these alterations could,in principle,confer effective tumor control while minimizing off-target effects.展开更多
Prof.Zhijian James Chen,a distinguished scientist in the field of innate immunity,has been honored with the 2025 Paul Ehrlich and Ludwig Darmstaedter Prize and the 2024 Albert Lasker Basic Medical Research Award for h...Prof.Zhijian James Chen,a distinguished scientist in the field of innate immunity,has been honored with the 2025 Paul Ehrlich and Ludwig Darmstaedter Prize and the 2024 Albert Lasker Basic Medical Research Award for his groundbreaking discovery of the enzyme cyclic guanosine monophosphate-adenosine monophosphate synthase(cGAS).His research has transformed the understanding of innate immune responses,particularly the role of cGAS as a cytosolic DNA sensor that triggers an interferon response.In this dialogue,Prof.Chen reflects on his research journey,from his initial exploration of ubiquitin and nuclear factor-kB(NF-kB)signaling to his discoveries of mitochondrial antiviral-signaling protein(MAVS)and cGAS,highlighting his lifelong interest in cell signaling and human diseases.The interview underscores the importance of perseverance and the pursuit of impactful research questions in scientific endeavors.This scholarly exchange offers a mentor-like perspective for aspiring scientists,encapsulating the essence of a successful career in biomedical research.展开更多
基金supported by the National Natural Science Foundation of China(82341042 and 32270993)the PhD program of the Interdisciplinary Research Center,Sun Yat-sen University.
文摘Tumor initiation and progression are highly intricate biolog-ical processes,and mutation-driven tumorigenesis is a pri-mary underlying cause.Personalized cancer vaccines have been developed to exploit these specific mutations,particu-larly in the form of tumor neoantigens,to induce immune responses,particularly the activation of CD8+T cells,which can attack malignant cells.Since tumor mutations result in protein sequence alterations distinct from those in normal tissues,therapies that precisely target these alterations could,in principle,confer effective tumor control while minimizing off-target effects.
文摘Prof.Zhijian James Chen,a distinguished scientist in the field of innate immunity,has been honored with the 2025 Paul Ehrlich and Ludwig Darmstaedter Prize and the 2024 Albert Lasker Basic Medical Research Award for his groundbreaking discovery of the enzyme cyclic guanosine monophosphate-adenosine monophosphate synthase(cGAS).His research has transformed the understanding of innate immune responses,particularly the role of cGAS as a cytosolic DNA sensor that triggers an interferon response.In this dialogue,Prof.Chen reflects on his research journey,from his initial exploration of ubiquitin and nuclear factor-kB(NF-kB)signaling to his discoveries of mitochondrial antiviral-signaling protein(MAVS)and cGAS,highlighting his lifelong interest in cell signaling and human diseases.The interview underscores the importance of perseverance and the pursuit of impactful research questions in scientific endeavors.This scholarly exchange offers a mentor-like perspective for aspiring scientists,encapsulating the essence of a successful career in biomedical research.
